References
- 1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
- 2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
- 3. Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010; 28: 355-8.
- 4. Neoptolemos IP, Stocken DD, Friess H, Bassi C, M.D., Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. NEJM 2004; 350: 1200-10.
- 5. Gastrointestinal Tumour Study Group. Radiation therapy combined with adriamycin or 5-Fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985; 56: 2563-8.
- 6. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3: 373-8.
- 7. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19: 1592-9.
- 8. Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An eastern cooperative oncology group trial. J Clin Oncol 2011; 29: 4105-12.
- 9. Conroy T, Desseigne F, Ychou M., Bouché O, Guimbaud R, Bécouarn Y, et al. For the Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25.
- 10. Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7(4): e1000267 2010.
- 11. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J Clin Oncol 2007; 25: 226-331.
- 12. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al: Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55.
- 13. Katrina F. Chu and Damian E. Dupuy. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nature Rev 2014; 14: 199-208.
- 14. Giardino A, Girelli R, Lusenti A, Auriemma A, Bassi C, Cantore M, et al. Triple approach strategy for patients with locally advanced pancreatic carcinoma. HPB (Oxford) 2013; 15: 623-7.
- 15. Girelli R, Gobbo S, Malleo G, Regi P, Salvia R, Frigerio I, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg 2013; 398: 63-9.
- 16. Cantore M, Frigerio I, Giardino A, Girelli R, Mambrini A, Orlandi M, et al: Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Brit J Surg 2012; 99: 1083-8.
- 17. Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, et al. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Brit J Surg 2010; 97: 220-5.
- 18. Shi X, L iu S, Kleeff J, Friess H, Büchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-62.
- 19. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-8.
- 20. Tamburrin o A, Piro G, Carbone C, Tortora G, Melisi D. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol 2013; 4: 56.
- 21. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
- 22. Li C, Hei dt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
- 23. Thiery JP , Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
- 24. Bria E, M ilella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, et al. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 2007; 110: 525-33.
- 25. Olson P, Hanahan D. Cancer. Breaching the cancer fortress. Science 2009; 324: 1400-1.
- 26. Neumann E , Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric field. EMBO J 1982; 1: 841-5.
- 27. Neumann E , Kakorin S, Toesing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg 1999; 48: 3-16.
- 28. Orlowski S, Mir LM. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta 1993; 1154: 51-63.
- 29. Gehl J. E lectroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003; 177: 437-47.
- 30. Mir LM, O rlowski S, Belehradek M and Paoletti C. Electrochemotherapy: potentiation of antitumor effect of bleomycin by local electric pulses. Eur J Cancer 1991; 1: 68-72.
- 31. Belehrade k M, Domenge C, Luboinski B, Orlowski S, Belehradek Jr. J, Mir LM. Electrochemotherapy, a new antitumor treatment - first clinical phase I‒II trial. Cancer 1993; 72: 3694-700.
- 32. Marty M, S ersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al: Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases. Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer 2006; S4: 3-13.
- 33. Sersa G, Sta buc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z. Electrochemotherapy with CDDP: potentiation of local CDDP antitumor effectiveness by application of electric pulses in cancer patients. Eur J Cancer 1998; 34: 1213-8.
- 34. Sersa G, Sta buc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863-7.
- 35. Matthiessen LW, Johannesen HH, Hendel HW, Moss T, Kamby C, Gehl J. Electrochemotherapy for large cutaneous recurrence of breast cancer: A phase II clinical trial. Acta Oncol 2012; 51: 713-21.
- 36. Mevio N, Ber tino G, Occhini A, Scelsi D, Tagliabue M, Mura F, et al. Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results. Tumori 2012; 98: 308-13.
- 37. Curatolo P, Quaglino P, Marenco F, Mancini M, Nardò T, Mortera C, et al. Electrochemotherapy in the treatment of kaposi sarcoma cutaneous lesions: A two-center prospective phase II trial. Ann Surg Oncol 2012; 1: 192-8.
- 38. Campana LG, Va lpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 2012; 99: 821-30.
- 39. Fini M, Salama nna F, Parrilli A, Martini L, Cadossi M, Maglio M, et al. Electrochemotherapy is effective in the treatment of rat bone metastases. Clin Exp Met 2013; 30: 1033-45.
- 40. Edhemovic I, G adzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011; 10: 475-85.
- 41. Edhemovic I, B recelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B et al. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 2014; 110: 320-7.
- 42. Heller R, Ja roszeski M, Perrot R, Messina J and Gilbert R: Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Melanoma Res 1997; 7: 10-8.
- 43. Sersa G., Cema zar M, Miklavcic D, Mir LM. Electrochemotherapy: variable anti-tumor effect on different tumor models. Bioelectrochem Bioenerg 1994; 35: 23-7.
- 44. Pendez S, Jaro szeski MJ, Gilbert R Hyacinthe M, Dang V, Hickey J, et al. Direct delivery of chemotherapeutic agents for the treatment of hepatoma and sarcoma in rat models. Radiol Oncol 1998; 21: 53-64.
- 45. Sersa G, Novak ovic S, Miklavcic D: Potentiation of bleomycin antitumor effectiveness by electrochemotherapy. Cancer Lett 1993; 69: 81-4.
- 46. Nanda GS, Sun FX, Hofmann GA, Hofmann RM, Dev SB. Electroporation enhances therapeutic efficacy of anticancer drugs: treatment of human pancreatic tumor in animal model. Anticancer Res 1988; 18: 1361-6.
- 47. Jaroszeski MJ, Gilbert RA, Heller R. In vivo antitumor effects of electrochemotherapy in a hepatoma model. Bioch Biophis Acta 1997; 1334: 15-8.
- 48. Ramirez LH, Or lowski S, An D, Gindoula G, Dzodic R, Ardouin P, et al. Electrochemotherapy on liver tumours in rabbit. Br. J Cancer 1998; 77: 2104-11.
- 49. Jaroszeski MJ, Illingworth P, Pottinger C, Hyacinthe M, Miller R. Electrically mediated drug delivery for treating subcutaneous and orthotopic pancreatic adenocarcinoma in a hamster model. Anticancer Res 1999; 19: 989-94.
- 50. Liu X, Tian X, Wang F, Ma Y, Kornmann M, Yang Y. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Eur J Cancer 2014; 50: 2251-62.
- 51. Granata V, Fus co R, Piccirillo M. Palaia R, Lastoria A, Petrillo A, et al. Feasibility and safety of intraoperative electrochemotherapy in locally pancreatic tumor: A preliminary experience. Eur J Inflamm 2014; 12: 467-77.
- 52. Allegretti JP, Panje WR. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 2001; 111: 52-6.
- 53. Bloom DC, Gold farb PM. The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck. Eur J Surg Oncol 2005; 31: 1029-35.
- 54. Miklavcic D, S ersa G, Brecelj E, Gehl J, Soden D, Bianchi G, Ruggieri P, Rossi CR, Campana LG, Jarm T. Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med Biol Eng Comput 2012; 50: 1213-25.
- 55. Todorovic V, S ersa G, Flisar K, Cemazar M. Enhanced cytotoxicity of bleomycin and cisplatin after electroporation in murine colorectal carcinoma cells. Radiol Oncol 2009; 43: 264-73.
- 56. Cemazar M, Tam zali Y, Sersa G, Tozon N, Mir LM, Miklavcic D, et al. Electrochemotherapy in veterinary oncology. J Vet Inter Med 2008; 22: 826-31.